Global Viral Safety Testing Market Growth (Status and Outlook) 2025-2031

According to this study, the global Viral Safety Testing market size will reach US$ 2148 million by 2031.

Viral safety testing is a critical set of procedures used to detect, quantify, and eliminate the presence of viruses in biological products, especially those intended for human use such as biopharmaceuticals, vaccines, blood products, and gene or cell therapies. This testing ensures that such products are free from contaminating or adventitious viruses, thereby safeguarding patient health and ensuring compliance with regulatory standards.

United States market for Viral Safety Testing is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

China market for Viral Safety Testing is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Europe market for Viral Safety Testing is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Global key Viral Safety Testing players cover Charles River, Eurofins BioPharma, Clean Cells, Texcell, Merck Millipore, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.

LPI (LP Information)' newest research report, the “Viral Safety Testing Industry Forecast” looks at past sales and reviews total world Viral Safety Testing sales in 2024, providing a comprehensive analysis by region and market sector of projected Viral Safety Testing sales for 2025 through 2031. With Viral Safety Testing sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Viral Safety Testing industry.

This Insight Report provides a comprehensive analysis of the global Viral Safety Testing landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Viral Safety Testing portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Viral Safety Testing market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Viral Safety Testing and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Viral Safety Testing.

This report presents a comprehensive overview, market shares, and growth opportunities of Viral Safety Testing market by product type, application, key players and key regions and countries.

Segmentation by Type:
Adventitious Virus Tests
Antibody Production Tests
Retrovirus Tests
Specific Virus Tests

Segmentation by Application:
Biopharmaceuticals
Medical Industry
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Charles River
Eurofins BioPharma
Clean Cells
Texcell
Merck Millipore
Syngene
CPHI Online
Nelson Labs
Sartorius Stedim BioOutsource Limited
WuXi Biologics
ViSpot Co., Ltd.
Syngene International Ltd.
Laboratory Corporation of America Holdings
Creative Biogene
Asahi Kasei Corporation

Please note: The report will take approximately 2 business days to prepare and deliver. Show more